A curated library of guides, compliance knowledge, and operational insights to help pharmaceutical teams navigate Open Payments reporting, manage HCP events, and streamline field workflows.
AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibitors.Read more
On September 9, 2026, the U.S. Food and Drug Administration, in partnership with the Reagan-Udall Foundation for the FDA (Foundation), will convene a public meeting to hear public comments on perspectives regarding the use of opioid medications for the management of pain and addiction.Read more
FDA awards a 5-year grant to the University of Maryland and the University of Michigan to establish a Center for Research on Complex Generics (CRCG).Read more
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.Read more
